购物车
- 全部删除
- 您的购物车当前为空
Moxifloxacin hydrochloride (BAY12-8039 HCl) 是一种口服有效的 8-甲氧基喹诺酮类抗菌药物,可研究感染性肺炎,急性细菌性鼻窦炎和慢性支气管炎的急性细菌性加重。
Moxifloxacin hydrochloride (BAY12-8039 HCl) 是一种口服有效的 8-甲氧基喹诺酮类抗菌药物,可研究感染性肺炎,急性细菌性鼻窦炎和慢性支气管炎的急性细菌性加重。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 372 | 现货 | |
50 mg | ¥ 492 | 现货 | |
100 mg | ¥ 738 | 现货 | |
200 mg | ¥ 1,090 | 现货 | |
500 mg | ¥ 1,930 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 225 | 现货 |
产品描述 | Moxifloxacin hydrochloride (BAY12-8039 HCl) is a fourth generation fluoroquinolone with expanded activity against gram-positive bacteria as well as atypical pathogens. Moxifloxacin has been linked to mild ALT elevations during therapy and to rare instances of idiosyncratic acute liver injury with symptoms and jaundice. |
体外活性 | 在模拟人体疾病的小鼠体内,与用异烟肼/利福平/吡嗪酰胺相比,Moxioxacin结合RIF/吡嗪酰胺减少2个月的治疗时间.类似的,利福平/Moxioxacin/吡嗪酰胺一周两次处理小鼠,在4个月之后达到稳定治愈,而利福平/异烟肼/吡嗪酰胺每天处理一次,6个月后治愈. |
体内活性 | Moxioxacin具有广谱的抗菌活性,对金黄色酿脓葡萄球菌,肺炎链球菌,化脓性链球菌,流感嗜血杆菌,H. parainuenzae,肺炎克雷伯菌,卡他莫拉菌,肺炎衣原体以及肺炎支原体表现出体外和临床活性。Moxioxacin通过诱捕DNA-药物-酶复合物发挥作用,其抑制了ATP依赖性的拓扑异构酶II(DNA促旋酶)和拓扑异构酶IV。 |
别名 | 盐酸莫西沙星, BAY-128039, Moxifloxacin HCl, BAY12-8039 HCl, 莫西沙星盐酸盐 |
分子量 | 437.89 |
分子式 | C21H25ClFN3O4 |
CAS No. | 186826-86-8 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
溶解度信息 | H2O: 15 mg/mL (34.3 mM) DMSO: 88 mg/mL (200.96 mM) Ethanol: < 1 mg/mL (insoluble or slightly soluble) | ||||||||||||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.